Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling

20252 citationsJournal Articlegold Open Access

Authors

Giuseppe Cecere · Roche (Switzerland)

Theresa M. Ballard · Roche (Switzerland)

Frédéric Knoflach · Roche (Switzerland)

Michael Honer · Roche (Switzerland)

Joerg F. Hipp · Roche (Switzerland)

Pilar Garcés · Roche (Switzerland)

Thomas Mueggler ·

Abstract

Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.

Topics & Keywords

Autism Spectrum Disorder Research GABA and Rice Research Neuroscience and Neuropharmacology Research

Publication Details

Published in: Frontiers in Pharmacology

Volume 16, pp. 1626078-1626078

DOI: 10.3389/fphar.2025.1626078

Field-Weighted Citation Impact: 2.94

Command Palette

Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling

Authors

Abstract

Topics & Keywords

Publication Details